May 16, 2017 Bio/Pharma/CRO Cell Analysis Tools Lab Top-10 M&A, Partnerships

MilliporeSigma’s CHOZN® Expression System Selected for Bi-specific Antibody Development by SystImmune

 Accelerates development timelines with faster, easier selection and scale up of clones  Delivers higher titers of recombinant proteins Billerica, Massachusetts, May 16, 2017 — MilliporeSigma today announced that its CHOZN® expression system will be used by SystImmune, a Seattle-based biotechnology company, for commercial development of a bi-specific antibody therapeutic. The CHOZN® expression system is designed... Read more